New combo therapy could open door to liver transplants for more patients
NCT ID NCT07310836
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This study looks at whether combining local treatments (like targeted radiation or chemo beads) with newer drugs (anti-VEGF/TKIs and immune checkpoint inhibitors) can shrink liver tumors enough for patients to qualify for a transplant. Researchers will review records of 300 patients, including about 100 who received this combo therapy. The goal is to see if this aggressive approach can safely turn ineligible patients into transplant candidates and improve their survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
locoregional therapies (like TACE or radiotherapy) plus anti-VEGF/TKIs and immune checkpoint inhibitors
What this could lead to
If successful, this approach could help more patients with advanced liver cancer become eligible for a life-saving transplant.
What could go wrong
This is a small, early retrospective study, not a controlled trial. The combination therapy may cause serious side effects, and it's unclear if it will improve long-term survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.